Skip to content

Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images

Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images:a Multi-center Prospective Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05202626
Enrollment
100
Registered
2022-01-21
Start date
2021-12-01
Completion date
2025-06-28
Last updated
2023-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Image-Guided Biopsy, Nasopharyngeal Carcinoma

Keywords

Artificial Intelligence, Classification, Nasopharyngeal Carcinoma, Nasopharyngoscope, Image-Guided Biopsy

Brief summary

Due to the occult anatomic location of the nasopharynx and frequent presence of adenoid hyperplasia, the positive rate for nasopharyngeal carcinoma identification during biopsy is low, thus leading to delayed or missed diagnosis for nasopharyngeal carcinoma upon initial attempt. Here, we aimed to develop an artificial intelligence tool to detect nasopharyngeal malignancies and guide biopsy under endoscopic examination based on deep learning.

Detailed description

Due to the occult anatomic location of the nasopharynx and frequent presence of adenoid hyperplasia, the positive rate for nasopharyngeal carcinoma identification during biopsy is low, thus leading to delayed or missed diagnosis for nasopharyngeal carcinoma upon initial attempt. Here, we aimed to develop an artificial intelligence tool to detect nasopharyngeal malignancies and guide biopsy under endoscopic examination based on deep learning.

Interventions

DIAGNOSTIC_TESTNasopharyngeal Endoscopy image-guided Biopsy

For each participant presenting with a suspicious nasopharyngeal lesion, the attending physician will assess the lesion and determine the appropriate biopsy approach. The physician may decide on multiple biopsies from the lesion area, including one sample from within the lesion itself, another from 5-8 mm outside the lesion, and a third from 8-10 mm beyond the lesion. Alternatively, a single biopsy may be deemed sufficient based on the clinical judgment. Each of these specimens will undergo pathological examination to confirm whether they are carcinomatous or non-carcinomatous.

Sponsors

Sun Yat-sen University
CollaboratorOTHER
Guangdong Provincial People's Hospital
CollaboratorOTHER
Nanfang Hospital, Southern Medical University
CollaboratorOTHER
Fujian Cancer Hospital
CollaboratorOTHER_GOV
Hainan People's Hospital
CollaboratorOTHER
Chinese Academy of Sciences
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient was found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy and the clinicans considered it necessary to perform an biopsy. * Hemilateral lesion with limited size.

Exclusion criteria

* Patients with nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, etc. who have already been treated.

Design outcomes

Primary

MeasureTime frameDescription
Aera under the receiver operating characteristic curve (AUC)three monthsAUC of an deep learning-based model in discriminating nasopharyngeal carcinoma from bengin lesion.

Secondary

MeasureTime frameDescription
Accuraythree monthsThe agreement between the deep learning-based model and the histopathological diagnosis of the three biopsy specimens (inside the lesion, 5-8 mm outside the lesion, and 8-10 mm outside the lesion).

Other

MeasureTime frameDescription
Statistical significanceThree yearsStatistical significance (P value) of DFS (time from diagnosis to disease progression or death from any cause) in nasopharyngeal carcinoma patients between high-risk and low-risk group identified by deep learning-based model.

Countries

China

Contacts

Primary ContactDi Dong, Ph.D
di.dong@ia.ac.cn+86 010-82618465
Backup ContactYali Zang, ph.D
yali.zang@ia.ac.cn

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026